The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / China Approves Use of Tocilizumab for Coronavirus Patients

China Approves Use of Tocilizumab for Coronavirus Patients

March 4, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

BEIJING (Reuters)—China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover.

You Might Also Like
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17

Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage and show elevated level of Interleukin 6 (IL-6), which could indicate inflammation or immunological diseases, the National Health Commission said in the latest version of its treatment guidelines published online.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Actemra can help contain inflammation related to IL-6, according to Roche.

However, there is no clinical trial evidence yet that the drug will be effective on coronavirus patients. Actemra also has not received approval from China’s National Medical Product Administration to be sold for use for coronavirus infections.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Chinese researchers recently registered a three-month clinical trial for Actemra that will recruit 188 coronavirus patients and take place from Feb. 10–May 10, according to records shown on China’s clinical trials registration database.

Roche could not be immediately reached for comment. On Monday, the firm said it donated 14 million yuan ($2.02 million) worth of Actemra during February.

The firm said in January it expects sales and profits growth this year as demand for new drugs and more business in China offsets declines in older medicines whose patents have expired.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Chinese drugmakers have been racing to develop alternatives to Roche’s treatment. Bio-Thera Solutions Ltd. expects to file new drug approval for its Actemra biosimilar in 2021, and Zhejiang Hisun Pharmaceutical Co Ltd. received in 2016 regulatory approval to conduct clinical trials for its tocilizumab candidate, company filings showed.

Filed Under: Drug Updates Tagged With: China, coronavirus, tocilizumab

You Might Also Like:
  • Roche Gets FDA Nod for Trial to Test Arthritis Drug on COVID-19 Patients
  • Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)